Really if they need cash so bad and thier attempts to pump ( 2nd half story/ Griffing report) keep failing then Chris needs to fall on his sword or swallow his pride and call Kirk and say we need some help can u do something to drum up investor confidence so we can fund these programs. Make the darn call.
Many investors r dumb. We all bought the story last year they just need some new people to buy the new story.
From what I understand it was never really started. No one enrolled. They try to fund this with grants and crossover with biodefense and they didn't want to waste the money on it. But they knew this last year when they said they were starting it. It was used to try to excite. The FDA did not have anything to do with this study stopping or it would have been released.
It will have to be. Trying to unload all those shares on Lincoln would be tough at these prices. And this is another lie. They stated in June they were good for at least another 12 months before tapping Lincoln. Or perhaps it was august. last Fall when they came out with the 2nd half 14 story it was a ploy to raise prices in order to get the cash to do these things. They were actually trying to pump the stock but it didn't work so now we get the delays and so at these prices unless 942 or Thermovax turns something positive. If they try to raise before data u know what that means.
hope do u know what our deal with SGX 94 is? I was taken back with our royalty payment for ORbec which wasn't a big ticket item to begin with. If 942 is successful do we have 100% ownership or are we getting gauged on this one too?
yes obviously it was too aggressive for them and heck Rivax has been too aggressive for 10 years the question is is the current timeline too agressive as well.
What a great time for Management to step in here and show us there confidence in the new timelines and program and buy some stock. If this is people overreacting to recent push in many programs then what a great opportunity for management to change the perception around here that they are not just collecting a paycheck and want to put some wieght behind the brochure. My guess is they won't and that is a very bad sign. CHRIS has got to go.
The only report I saw was the one from 10 which is outdated. I only saw a blurb about todays release but not the report. Today's release is not by accident I'm sure it's coordinated to try to drum up price. Last year it was the exciting 2nd half of 14, which I patiently waited for, they are hoping this year it will be 942 data and a new program. Chris needs to go.
Griffin did a similar report back in 2010. THey r plenty aware of SNGX. If u can pull that report up it is quite interesting to read in comparison to recent events. It is very extensive in the Orbec study which shows how the endpoint data in 06 did not hit however the secondary data did look very good. However its interesting to see that we only would recieve 35 % royalty on success with orbec in the us per our deal with Sigma Tau.
done plenty of dd. u miss the point of my post. I'm simply outlining how I would expect management here to frame things moving forward. I called this a brochure company months ago and stated we will see how the brochure plays out to which u often complained to me about.
What really happened here besides I think we got lied to about Orbec. I think the company was filling this in to look good knowing it wasn't going anywhere especially without additional funding which hadn't come. So we were suppose to have 2 phase 2 data and 2 phase 2 starts this half or early 15. Instead we now know Orbec is dead but we got phase 2 data with a phase 3 start first half 15 with a drug candidate with higher market potential (PLUS). We r still getting phase 2 data from our lead candidate 942 in Early 15 with a little later phase 3 start if successful. But we know its enrolling and according to my conversation with managment has been enrolling since december of last year which means several of the 78 patients have been through the process and the company is confident about releasing data early 15 which tells me its got a chance. Instead of starting two phase 2 this year by next spring we should have a phase 2/3 and a phase 3 started(plus). Data isn't expected for 18 months after that which is disappointing but all in all when thinking about what was suppose to happen here by year end we aren't that far off and perhaps better off it just we got lied to about some timelines. I think this happens alot in biotech but I will say if u look at the past history of this company it happens way too much. But the fact is its going to take money to fund these programs and I think they expected to have a bit higher pps to generate some cash. So if they have to delay things a bit to conserve on shares it might be best in the long run.
The risk reward here is still in our favor but maybe only for a while longer. The only one playing games is management with their brochure. Hopefully its been purged of deceit now and management knows not to do this again.
No one is being critical of anyone's decision to buy or sell. What makes business sense to one person doesn't have to apply to others business decisions.